









Markets
/
Stocks
/
nasdaq-pbyi
/

Puma Biotechnology Inc

PBYI

6.940USD

+0.150+2.21%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

349.67MMarket Cap

9.25P/E TTM



Puma Biotechnology Inc

6.940

+0.150+2.21%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Puma Biotechnology Inc

Currency: USD Updated: 2026-02-06

Key Insights

Puma Biotechnology Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 64 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 5.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Puma Biotechnology Inc's Score

Industry at a Glance

Industry Ranking

64 / 159

Overall Ranking

178 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Puma Biotechnology Inc Highlights

StrengthsRisks

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 230.47M.

Fairly Valued

The company’s latest PE is 9.25, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 35.99M shares, decreasing 18.40% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.28K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.12.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

5.000

Target Price

-29.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Puma Biotechnology Inc is 8.37, ranking 72 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 54.48M, representing a year-over-year decrease of 32.36%, while its net profit experienced a year-over-year decrease of 56.47%.

Score

Industry at a Glance

Previous score

8.37

Change



Financials

8.45

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.02

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.06

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.32

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Puma Biotechnology Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Puma Biotechnology Inc is 5.76, ranking 142 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 9.25, which is 1302884.43% below the recent high of 120500.00 and 822.88% above the recent low of -66.85.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 64/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Puma Biotechnology Inc is 6.00, ranking 135 out of 159 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 7.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

5.000

Target Price

-29.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Puma Biotechnology Inc

PBYI

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Puma Biotechnology Inc is 9.12, ranking 38 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.47 and the support level at 6.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.98

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.028

Buy

RSI(14)

61.824

Neutral

STOCH(KDJ)(9,3,3)

65.384

Neutral

ATR(14)

0.361

Low Volatility

CCI(14)

78.910

Neutral

Williams %R

33.659

Buy

TRIX(12,20)

0.574

Sell

StochRSI(14)

29.001

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

6.950

Sell

MA10

6.698

Buy

MA20

6.577

Buy

MA50

6.008

Buy

MA100

5.529

Buy

MA200

4.635

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Puma Biotechnology Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 71.43%, representing a quarter-over-quarter increase of 1.62%. The largest institutional shareholder is The Vanguard, holding a total of 3.80M shares, representing 7.54% of shares outstanding, with 1.95% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Auerbach (Alan H)

6.90M

-0.68%

Acorn Capital Advisors, LLC

4.13M

The Vanguard Group, Inc.

Star Investors

3.69M

-0.40%

BlackRock Institutional Trust Company, N.A.

2.93M

-2.48%

Renaissance Technologies LLC

Star Investors

2.15M

+14.75%

Acadian Asset Management LLC

2.05M

+2.25%

American Century Investment Management, Inc.

1.48M

+10.50%

Dimensional Fund Advisors, L.P.

1.27M

+10.59%

Athyrium Capital Management, LP

1.26M

Geode Capital Management, L.L.C.

983.52K

+1.22%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Puma Biotechnology Inc is 4.63, ranking 87 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Puma Biotechnology Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.